New Alzheimer’s treatment: Revolutionary advances in dementia diagnosis and care

Learn about the new treatment for Alzheimer’s disease. Lecanemab and donanemab slow progression by 30%: Insights on biomarkers and eligibility.

Author: Sara Thompson

Published: January 14, 2026

Dementia care is experiencing a revolutionary shift. For decades, physicians had little to offer patients beyond symptomatic treatments and supportive care. Today, the medical community stands at the edge of a new era — one defined by precise biomarker testing and disease-modifying therapies that represent  genuine new treatments for Alzheimer’s disease.

Understanding the new treatment for Alzheimer’s disease

The approval of lecanemab in 2023 and donanemab in 2024 represents the most significant advance in Alzheimer’s treatment in decades. These monoclonal antibodies constitute the first new treatment for Alzheimer’s to address the underlying disease process rather than merely managing symptoms. Unlike traditional cognitive enhancers, these medications target and remove amyloid beta plaques from the brain — the protein deposits believed to trigger the disease cascade.

The diagnostic landscape: Beyond clinical assessment

However, these treatments may only be effective very early in the course of Alzheimer’s Disease, making new advances in early diagnosis critical. While history-taking remains the cornerstone of dementia evaluationphysicians now have tools that can confirm clinical suspicions with unprecedented precision. These advances are essential for determining which patients are appropriate candidates for the new treatment for Alzheimer’s.

The amyloid hypothesis has guided much of this progress. This framework proposes that beta-amyloid deposition triggers a cascade of events: synaptic dysfunction, tau-mediated injury, brain atrophy and, ultimately, cognitive decline. Understanding this sequence has allowed researchers to develop biomarkers that detect disease years before symptoms emerge.

The biomarker revolution

Until recently, cerebrospinal fluid (CSF) analysis represented the gold standard for biomarker testing. By measuring ratios of beta-amyloid 42 to 40 and phosphorylated tau (pTau) 181 to beta-amyloid 42, physicians could identify the molecular fingerprint of Alzheimer’s disease. As amyloid precipitates in the brain, CSF levels fall while tau levels rise — a hallmark pattern.

Amyloid PET scanning offers a complementary approach, directly visualizing amyloid deposition in the brain. However, both methods face practical barriers: patients often resist lumbar punctures, and PET scans are often unavailable in many areas.

Blood-based biomarkers represent the newest diagnostic advancement. Multiple tests are now available, with pTau-217 emerging as the most accurate marker — achieving more than 90% sensitivity and specificity in some formulations, approaching the performance of CSF analysis. Counterintuitively, pTau-217 proves to be an excellent marker for amyloid deposition while being only moderately useful for detecting tau pathology itself.

However, blood-based biomarkers require careful interpretation. Their accuracy depends heavily on pretest probability — a positive result means more when clinical suspicion is high, while positive results in unlikely cases remain difficult to interpret. Additionally, performance degrades in patients with significant renal disease or obesity. Most critically, these tests should never be performed without objective evidence of cognitive impairment. Testing cognitively normal individuals inevitably produces false positives, raising the troubling question: What should physicians tell someone with positive biomarkers who may never develop symptoms?

How the new treatment for Alzheimer’s works

Both lecanemab and donanemab are monoclonal antibodies that target slightly different areas of the amyloid molecule. This new treatment for Alzheimer’s effectively clears amyloid deposits, with most patients achieving clearance within 12 to 18 months. Clinical trial data shows that this new treatment for Alzheimer’s slows disease progression by approximately 30% in appropriate candidates.

Preliminary evidence suggests even greater benefit — perhaps 50% to 60% slowing — when the new treatment for Alzheimer’s begins very early in the disease course. Long-term data now demonstrate that the gap between treated and untreated patients continues to widen over time. At 36 months, the difference is roughly twice what researchers observe at 18 months — strong evidence that this new treatment for Alzheimer’s truly alters disease trajectory rather than providing temporary symptomatic relief.

Patient selection criteria

The new treatment for Alzheimer’s works best in a narrow window. Patients must have confirmed amyloid deposition through biomarker testing, mild cognitive impairment or mild dementia (MMSE 20 or above), and the ability to undergo regular MRI monitoring. The medications are administered as intravenous infusions: lecanemab every two weeks and donanemab every four weeks.

However, expectations must remain realistic. This new treatment for Alzheimer’s is not a cure. Patients continue to decline, just at a slower rate. The therapy represents important progress in modifying disease course, but families need to understand both the benefits and limitations.

Safety considerations

The primary safety concern with the new treatment for Alzheimer’s involves ARIA — amyloid-related imaging abnormalities. This encompasses both brain edema (ARIA-E) and microhemorrhages (ARIA-H). While imaging abnormalities occur in 20% to 30% of patients receiving these medications, symptomatic ARIA affects only 3% to 6%.

Most ARIA events occur within the first three to four months of treatment, necessitating intensive MRI monitoring during this period. Current guidelines recommend avoiding anticoagulation due to bleeding risk, though this may evolve as physicians gain more experience with the new treatment for Alzheimer’s. Patients with significant cerebral amyloid angiopathy or extensive vascular disease face higher risks and generally should not receive these treatments.

The cost of treatment — approximately $30,000 annually for the medication alone, rising to $40,000 to $50,000 with infusion fees and MRI monitoring — presents another barrier. Medicare provides good coverage, though Medicare Advantage plans prove more challenging. Patient assistance programs have helped many eligible patients access this new treatment for Alzheimer’s.

The future of Alzheimer’s treatment

The medical community stands at an inflection point in dementia care. Biomarkers allow physicians to diagnose Alzheimer’s disease with confidence before symptoms become severe. The new treatment for Alzheimer’s can slow progression during the critical window when intervention matters most. While these advances represent important steps rather than definitive solutions, they fundamentally change the approach to this devastating illness.

The next frontier involves earlier detection and treatment. If physicians can identify at-risk individuals years before symptoms appear and intervene at that stage, they may be able to prevent dementia entirely. The current new treatment for Alzheimer’s provides proof of concept; researchers anticipate even more effective therapies in the coming years.

Clinical pearls

  • History remains paramount. Talking with patients and informants provides the diagnosis in most cases. New biomarker studies can help confirm a diagnosis when used appropriately. When patients insist they have Alzheimer’s disease, they usually don’t. When family members express concern while patients minimize problems, Alzheimer’s becomes much more likely.
  • Confirm amyloid before prescribing the new treatment for Alzheimer’s. Patients must have documented amyloid deposition through CSF analysis, amyloid PET scan or validated blood biomarkers. Prescribing antiamyloid therapy without confirming amyloid presence is inappropriate and potentially harmful.
  • Blood biomarkers require careful context. Never order biomarker tests without objective cognitive impairment. Results depend heavily on pretest probability. Particularly in patients without renal disease or obesity, pTau-217 offers the best performance but remains imperfect.
  • CSF analysis remains the gold standard. While patients often resist lumbar puncture, the procedure is straightforward and provides the most reliable biomarker data. Look for falling amyloid 42 and rising phosphorylated tau — the molecular signature of Alzheimer’s disease.
  • The new treatment for Alzheimer’s works best early. Patients must have mild cognitive impairment or mild dementia (MMSE equal to or greater than 20 to 22), confirmed amyloid deposition and ability to undergo MRI monitoring. The earlier treatment begins, the greater the potential benefit.
  • ARIA monitoring is essential but manageable. Most amyloid-related imaging abnormalities occur in the first three to four months and remain asymptomatic. Intensive MRI monitoring during early treatment allows safe continuation in most cases. Symptomatic ARIA affects only 3% to 6% of patients.
  • Visual hallucinations suggest Lewy body disease. Well-formed visual hallucinations of people or animals appearing early in relatively mild dementia should raise strong suspicion for Lewy body disease rather than Alzheimer’s disease — a condition for which the new treatment for Alzheimer’s would be inappropriate.
  • Don’t forget cholinesterase inhibitors. While the new treatment for Alzheimer’s garners attention, donepezil, rivastigmine, galantamine and memantine remain valuable. These cognitive enhancers provide modest symptomatic benefit, are generally well-tolerated and work across multiple dementia subtypes.
  • MRI findings matter beyond ruling out lesions. Extensive white matter changes suggest vascular contributions to dementia. This may indicate vascular dementia as the primary diagnosis or increase ARIA risk with the new treatment for Alzheimer’s. Both scenarios warrant careful consideration before treatment.
  • Treatment benefits accumulate over time. The gap between treated and untreated patients widens progressively. At 36 months, the difference is roughly double what researchers observe at 18 months — evidence that the new treatment for Alzheimer’s genuinely modifies disease course rather than providing temporary symptomatic relief.
  • Set realistic expectations. The new treatment for Alzheimer’s slows progression by approximately 30%, not stops or reverses it. Patients continue to decline, just at a more gradual rate. This represents important progress, but families need to understand limitations alongside benefits.